• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Sage Therapeutics Inc.

    6/25/24 4:06:10 PM ET
    $SAGE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SAGE alert in real time by email
    S-8 1 d854350ds8.htm S-8 S-8

    As filed with the Securities and Exchange Commission on June 25, 2024

    Registration No. 333-   

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

     

    SAGE THERAPEUTICS, INC.

    (Exact Name of Registrant as Specified in Its Charter)

     

     

     

    Delaware   27-4486580

    (State or Other Jurisdiction of

    Incorporation or Organization)

     

    (I.R.S. Employer

    Identification No.)

    215 First Street

    Cambridge, MA 02142

      02142
    (Address of Principal Executive Offices)   (Zip Code)

     

     

    Sage Therapeutics, Inc. 2024 Equity Incentive Plan

    (Full Title of the Plan)

    Barry E. Greene

    President and Chief Executive Officer

    Sage Therapeutics, Inc.

    215 First Street

    Cambridge, MA 02142

    (Name and Address of Agent For Service)

    (617) 299-8380

    (Telephone Number, Including Area Code, of Agent For Service)

    Copies to:

    Anne Marie Cook

    Senior Vice President, General Counsel

    Sage Therapeutics, Inc.

    215 First Street

    Cambridge, MA 02142

    (617) 299-8380

    Stuart M. Falber, Esq.

    Rosemary G. Reilly, Esq.

    C.S. Avery Reaves, Esq.

    Wilmer Cutler Pickering Hale and Dorr LLP

    60 State Street

    Boston, MA 02109

    (617) 526-6000

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer

     

    ☒

      

    Accelerated filer

     

    ☐

    Non-accelerated filer

     

    ☐

      

    Smaller reporting company

     

    ☐

        

    Emerging growth company

     

    ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     

     


    PART I

    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

    Item 1. Plan Information.

    The information required by Item 1 is omitted from this registration statement and included in documents sent or given to participants in the plan covered by this registration statement pursuant to Rule 428(b)(1) of the Securities Act of 1933, as amended (the “Securities Act”).

    Item 2. Registrant Information and Employee Plan Annual Information.

    The written statement required by Item 2 is omitted from this registration statement and included in documents sent or given to participants in the plan covered by this registration statement pursuant to Rule 428(b)(1) of the Securities Act.

    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

    Item 3. Incorporation of Documents by Reference.

    The registrant is subject to the informational and reporting requirements of Sections 13(a), 14, and 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and in accordance therewith files reports, proxy statements and other information with the Securities and Exchange Commission (the “Commission”). The following documents, which are on file with the Commission, are incorporated in this registration statement by reference:

    (a) the registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, as filed with the Commission on February 14, 2024, including the information specifically incorporated by reference into the Annual Report on Form 10-K from the registrant’s definitive proxy statement for the 2024 Annual Meeting of Stockholders;

    (b) the registrant’s Quarterly Report on Form 10-Q for the fiscal quarter ended March  31, 2024, as filed with the Commission on April 25, 2024;

    (c) the registrant’s Current Reports on Form 8-K as filed with the Commission on January  8, 2024, January  24, 2024, January  31, 2024, March  26, 2024, April  19, 2024, June  11, 2024 and June 11, 2024; and

    (d) The description of the registrant’s common stock contained in its Registration Statement on Form 8-A (File No. 001-36544) as filed with the Commission on July 15, 2014, as the description therein has been updated and superseded by the description of the registrant’s capital stock contained in Exhibit 4.2 to its Annual Report on Form 10-K for the fiscal year ended December 31, 2023, as filed with the Commission on February 14, 2024, including any amendments and reports filed for the purpose of updating such description.

    All documents subsequently filed by the registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act, prior to the filing of a post-effective amendment that indicates that all securities offered hereby have been sold or that deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference in this registration statement and to be part hereof from the date of the filing of such documents. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for the purposes of this registration statement to the extent that a statement contained herein or in any other subsequently filed document that also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this registration statement.


    Item 4. Description of Securities.

    Not applicable.

    Item 5. Interests of Named Experts and Counsel.

    Not applicable.

    Item 6. Indemnification of Directors and Officers.

    The following summary is qualified in its entirety by reference to the complete Delaware General Corporation Law (the “DGCL”); the registrant’s amended and restated certificate of incorporation (the “Certificate of Incorporation”); and the registrant’s amended and restated bylaws (the “Bylaws”).

    Section 145 of the DGCL provides, generally, that a corporation shall have the power to indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding (except actions by or in the right of the corporation) by reason of the fact that such person is or was a director, officer, employee or agent of the corporation against all expenses, judgments, fines and amounts paid in settlement actually and reasonably incurred by such person in connection with such action, suit or proceeding if such person acted in good faith and in a manner such person reasonably believed to be in or not opposed to the best interests of the corporation and, with respect to any criminal action or proceeding, had no reasonable cause to believe his or her conduct was unlawful. A corporation may similarly indemnify such person for expenses actually and reasonably incurred by such person in connection with the defense or settlement of any action or suit by or in the right of the corporation, provided that such person acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the best interests of the corporation, and, in the case of claims, issues and matters as to which such person shall have been adjudged liable to the corporation, provided that a court shall have determined, upon application, that, despite the adjudication of liability but in view of all of the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses which such court shall deem proper.

    Section 102(b)(7) of the DGCL provides, generally, that a corporation’s certificate of incorporation may contain a provision eliminating or limiting the personal liability of a director or officer to the corporation or its stockholders for monetary damages for breach of fiduciary duty as a director or officer, provided that such provision may not eliminate or limit the liability of (i) a director or officer for any breach of the director’s duty of loyalty to the corporation or its stockholders, (ii) a director or officer for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (iii) a director under Section 174 of the DGCL, (iv) a director or officer for any transaction from which the director or officer derived an improper personal benefit, or (v) an officer in any action by or in the right of the corporation. No such provision may eliminate or limit the liability of a director or officer for any act or omission occurring prior to the date when such provision became effective.

    Article VII of the registrant’s Certificate of Incorporation provides that a director of the registrant shall not be personally liable to the registrant or its stockholders for monetary damages for breach of fiduciary duty as a director, except for liability (1) for any breach of the director’s duty of loyalty to the registrant or its stockholders, (2) for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (3) under Section 174 of the DGCL, or (4) for any transaction from which the director derived an improper personal benefit. In addition, the registrant’s Certificate of Incorporation provides that if the DGCL is amended to authorize the further elimination or limitation of the liability of directors, then the liability of a director of the registrant shall be eliminated or limited to the fullest extent permitted by the DGCL, as so amended.

    Article VII of the registrant’s Certificate of Incorporation further provides that any amendment, repeal or modification of such article by the registrant’s stockholders or amendment to the DGCL shall not adversely affect any right or protection existing at the time of such amendment, repeal or modification with respect to any acts or omissions occurring before such amendment, repeal or modification of a director serving at the time of such amendment, repeal or modification.

    Article V of the registrant’s Bylaws provides that the registrant will indemnify each of its directors and officers and, in the discretion of its board of directors, certain employees, to the fullest extent permitted by the DGCL as the same may be amended (except that in the case of an amendment, only to the extent that the amendment permits the registrant to provide broader indemnification rights than the DGCL permitted the registrant to provide prior to such


    amendment) against any and all expenses, judgments, damages, liabilities, losses, penalties, excise taxes, fines and amounts paid in settlement that are incurred by the director, officer or such employee or on the director’s, officer’s or employee’s behalf in connection with any threatened, pending or completed proceeding or any claim, issue or matter therein, to which he or she is or is threatened to be made a party because he or she is or was serving as a director, officer or employee of the registrant, or at the registrant’s request as a director, partner, trustee, officer, employee or agent of another corporation, partnership, joint venture, trust, employee benefit plan or other enterprise, if he or she acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the best interests of the registrant and, with respect to any criminal proceeding, had no reasonable cause to believe his or her conduct was unlawful. Article V of the registrant’s Bylaws further provides for the advancement of expenses to each of the registrant’s directors and, in the discretion of the board of directors, to certain officers and employees.

    In addition, Article V of the registrant’s Bylaws provides that the right of each of the registrant’s directors and officers to indemnification and advancement of expenses shall be a contract right and shall not be exclusive of any other right now possessed or hereafter acquired under any statute, provision of the registrant’s Certificate of Incorporation or Bylaws, agreement, vote of stockholders or otherwise. Furthermore, Article V of the registrant’s Bylaws authorizes the registrant to provide insurance for its directors, officers and employees, against any liability, whether or not the registrant would have the power to indemnify such person against such liability under the DGCL or the provisions of Article V of the registrant’s Bylaws.

    The registrant has entered into indemnification agreements with each of its directors and executive officers. These agreements provide that the registrant will indemnify each of its directors and executive officers to the fullest extent permitted by law and the registrant’s Certificate of Incorporation and Bylaws.

    The registrant maintains a general liability insurance policy which covers certain liabilities of the directors and officers of the registrant arising out of claims based on acts or omissions in their capacities as directors or officers.

    Item 7. Exemption from Registration Claimed.

    Not applicable.

    Item 8. Exhibits.

    The following exhibits are incorporated herein by reference:

     

    Exhibit
    No.
     

    Description

     4.1   Fifth Amended and Restated Certificate of Incorporation of the Registrant, as currently in effect (incorporated by reference to Exhibit 3.1 of the Registrant’s Current Report on Form 8-K (File No. 000-36544) filed on July 25, 2014)
     4.2   Amended and Restated Bylaws of the Registrant, as currently in effect (incorporated by reference to Exhibit 3.1 of the Registrant’s Current Report on Form 8-K (File No. 001-36544) filed on June 16, 2023)
     5.1   Opinion of Wilmer Cutler Pickering Hale and Dorr LLP, counsel to the Registrant
    23.1   Consent of Wilmer Cutler Pickering Hale and Dorr LLP (included in Exhibit 5.1)
    23.2   Consent of PricewaterhouseCoopers LLP, an independent registered public accounting firm
    24.1   Power of attorney (included on the signature pages of this registration statement)
    99.1(1)   2024 Equity Incentive Plan
    107   Filing Fee Table

     

    (1)

    Previously filed with the Securities and Exchange Commission as Appendix A to the registrant’s definitive proxy statement on Schedule 14A (File No. 001-36544) filed with the Securities and Exchange Commission on April 24, 2024 and incorporated herein by reference.


    Item 9. Undertakings.

    1. The undersigned registrant hereby undertakes:

     

      (1)

    To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:

     

      (i)

    To include any prospectus required by Section 10(a)(3) of the Securities Act;

     

      (ii)

    To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement; and

     

      (iii)

    To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement;

    provided, however, that paragraphs (1)(i) and (ii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in the registration statement.

     

      (2)

    That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

      (3)

    To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

    2. The undersigned registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

    3. Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Cambridge, Commonwealth of Massachusetts, on the 25th day of June, 2024.

     

    SAGE THERAPEUTICS, INC.

    By:   /s/ Barry E. Greene
      Barry E. Greene
      Chief Executive Officer, President and Director

    POWER OF ATTORNEY AND SIGNATURES

    We, the undersigned officers and directors of Sage Therapeutics, Inc., hereby severally constitute and appoint Barry E. Greene and Kimi Iguchi, and each of them singly (with full power to each of them to act alone), our true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution in each of them for him or her and in his or her name, place and stead, and in any and all capacities, to sign for us and in our names in the capacities indicated below this registration statement on Form S-8 and any and all amendments (including post-effective amendments) to this registration statement on Form S-8, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite or necessary to be done in and about the premises, as full to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents or any of them, or their or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed by the following persons in the capacities and on the date indicated below.

     

    Signature

      

    Title

     

    Date

    /s/ Barry E. Greene

    Barry E. Greene

      

    Chief Executive Officer, President and Director

    (Principal Executive Officer)

      June 25, 2024

    /s/ Kimi Iguchi

    Kimi Iguchi

       Chief Financial Officer (Principal Financial and Accounting Officer)   June 25, 2024

    /s/ Michael F. Cola

    Michael F. Cola

      

    Director

      June 25, 2024

    /s/ Jessica Federer

    Jessica Federer

      

    Director

      June 25, 2024

    /s/ James Frates

    James Frates

      

    Director

      June 25, 2024

    /s/ Geno Germano

    Geno Germano

      

    Director

      June 25, 2024

    /s/ Jeffrey M. Jonas, M.D.

    Jeffrey M. Jonas, M.D.

      

    Director

      June 25, 2024


    /s/ Elizabeth Barrett

    Elizabeth Barrett

      

    Director

      June 25, 2024

    /s/ George Golumbeski, Ph.D.

    George Golumbeski, Ph.D.

      

    Director

      June 25, 2024
    Get the next $SAGE alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SAGE

    DatePrice TargetRatingAnalyst
    3/11/2025$5.00Underperform
    BofA Securities
    11/21/2024$4.00Underperform → Sector Perform
    RBC Capital Mkts
    10/10/2024Mkt Perform
    Raymond James
    10/4/2024$10.00 → $4.00Outperform → Sector Perform
    RBC Capital Mkts
    7/30/2024$16.00 → $10.00Buy → Hold
    TD Cowen
    7/25/2024$18.00 → $12.00Overweight → Neutral
    JP Morgan
    5/29/2024$15.00Neutral
    Robert W. Baird
    5/29/2024$8.00Sell
    Citigroup
    More analyst ratings

    $SAGE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Officer Quirk Michael C. returned 32,961 shares to the company, closing all direct ownership in the company (SEC Form 4)

    4 - Sage Therapeutics, Inc. (0001597553) (Issuer)

    7/31/25 12:04:37 PM ET
    $SAGE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Federer Jessica

    4 - Sage Therapeutics, Inc. (0001597553) (Issuer)

    7/31/25 12:03:01 PM ET
    $SAGE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Operating Officer Benecchi Christopher returned 64,428 shares to the company, closing all direct ownership in the company (SEC Form 4)

    4 - Sage Therapeutics, Inc. (0001597553) (Issuer)

    7/31/25 11:57:08 AM ET
    $SAGE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SAGE
    SEC Filings

    View All

    SEC Form 15-12G filed by Sage Therapeutics Inc.

    15-12G - Sage Therapeutics, Inc. (0001597553) (Filer)

    8/11/25 5:00:17 PM ET
    $SAGE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form POSASR filed by Sage Therapeutics Inc.

    POSASR - Sage Therapeutics, Inc. (0001597553) (Filer)

    8/1/25 5:22:10 PM ET
    $SAGE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form POSASR filed by Sage Therapeutics Inc.

    POSASR - Sage Therapeutics, Inc. (0001597553) (Filer)

    8/1/25 5:21:50 PM ET
    $SAGE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SAGE
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    August 4, 2023 - La FDA aprueba el primer tratamiento oral para la depresión posparto

    For Immediate Release: August 04, 2023 El día de hoy, la Administración de Alimentos y Medicamentos de los Estados Unidos (FDA, por sus siglas en inglés) aprobó Zurzuvae (zuranolona), el primer medicamento oral indicado para tratar la depresión posparto (DPP) en mujeres adultas. La DPP es un episodio depresivo grave que generalmente ocurre después del parto, pero también puede comenzar durante las últimas etapas

    8/8/23 9:34:19 AM ET
    $SAGE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    August 4, 2023 - FDA Approves First Oral Treatment for Postpartum Depression

    For Immediate Release: August 04, 2023 Today, the U.S. Food and Drug Administration approved Zurzuvae (zuranolone), the first oral medication indicated to treat postpartum depression (PPD) in adults. PPD is a major depressive episode that typically occurs after childbirth but can also begin during the later stages of pregnancy. Until now, treatment for PPD was only available as an IV injection given by a health

    8/4/23 6:50:31 PM ET
    $SAGE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SAGE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Supernus Pharmaceuticals Completes Acquisition of Sage Therapeutics

    ROCKVILLE, Md., July 31, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) ("Supernus") today announced that it has successfully completed its previously announced acquisition of Sage Therapeutics, Inc. (NASDAQ:SAGE) ("Sage"). "Sage is an ideal fit in our corporate development strategy, adding a significant fourth growth product to our portfolio and further diversifying our sources of future revenue," said Jack Khattar, President and CEO of Supernus Pharmaceuticals. "With our proven track record of strong commercial execution along with the expected cost synergies, the acquisition is expected to be accretive in 2026." Compelling Strategic Rationale Strengthens psychi

    7/31/25 8:44:03 AM ET
    $SAGE
    $SUPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sage Therapeutics Announces Second Quarter 2025 Financial Results

    Achieved $23.2 million in ZURZUVAE® (zuranolone) collaboration revenue in the second quarter of 2025 (50% of the net revenues recorded by Biogen), representing a 68% increase from the first quarter Previously announced acquisition by Supernus Pharmaceuticals expected to close in third quarter of 2025 Cash, cash equivalents, and marketable securities of $366 million as of June 30, 2025 Sage Therapeutics, Inc. (NASDAQ:SAGE), today reported business highlights and financial results for the second quarter ended June 30, 2025. "Our second quarter results reflect revenue acceleration driven by increased investment, strong execution, and growing momentum behind ZURZUVAE, underscoring our c

    7/30/25 4:05:00 PM ET
    $SAGE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Supernus Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Sage Therapeutics, Inc. Tender Offer

    ROCKVILLE, Md., July 28, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc., a Delaware corporation (NASDAQ:SUPN) ("Supernus", and the "Company"), today announced that the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR Act"), with respect to Supernus' proposed acquisition of Sage Therapeutics, Inc., a Delaware corporation (NASDAQ:SAGE) ("Sage"), expired at 11:59 p.m. Eastern Time on July 25, 2025. On June 13, 2025, Supernus and Sage, entered into an Agreement and Plan of Merger (the "Merger Agreement"), by and among Supernus, Sage and Saphire, Inc., a Delaware corporation and a wholly owned subsidiary of Supernus ("Purchaser")

    7/28/25 8:25:15 AM ET
    $SAGE
    $SUPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SAGE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    BofA Securities resumed coverage on SAGE Therapeutics with a new price target

    BofA Securities resumed coverage of SAGE Therapeutics with a rating of Underperform and set a new price target of $5.00

    3/11/25 7:43:31 AM ET
    $SAGE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SAGE Therapeutics upgraded by RBC Capital Mkts with a new price target

    RBC Capital Mkts upgraded SAGE Therapeutics from Underperform to Sector Perform and set a new price target of $4.00

    11/21/24 7:42:56 AM ET
    $SAGE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Raymond James resumed coverage on SAGE Therapeutics

    Raymond James resumed coverage of SAGE Therapeutics with a rating of Mkt Perform

    10/10/24 8:30:27 AM ET
    $SAGE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SAGE
    Leadership Updates

    Live Leadership Updates

    View All

    Phathom Pharmaceuticals Appoints Anne Marie Cook as Chief Legal Officer and Corporate Secretary

    FLORHAM PARK, N.J., June 23, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced the appointment of Anne Marie Cook, J.D., as Chief Legal Officer and Corporate Secretary. Ms. Cook is an accomplished pharmaceutical legal executive with a proven track record advising pharmaceutical companies and broad expertise in corporate governance, commercial law, regulatory compliance, strategic transactions and legal strategy. Ms. Cook most recently served as Senior Vice President, General Counsel of Sage Therapeutics, Inc. and previously se

    6/23/25 7:59:57 AM ET
    $PHAT
    $SAGE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sage Therapeutics Announces R&D Leadership Transition

    Sage Therapeutics, Inc. (NASDAQ:SAGE) today announced that Dr. Laura Gault, Chief Medical Officer, has decided to pursue a new opportunity and will depart the Company, effective March 21, 2025. Dr. Gault joined Sage Therapeutics in November 2022 and has led the Company's product pipeline through all stages of development. Mike Quirk, Chief Scientific Officer, will assume key responsibilities, including strategic guidance for clinical development programs, on an interim basis. "I would like to extend my sincerest gratitude to Laura for her leadership and dedication to advancing innovation for patients with debilitating brain health conditions," said Barry Greene, Chief Executive Officer of

    3/4/25 4:15:00 PM ET
    $SAGE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sage Therapeutics Appoints Jessica Federer to Board of Directors

    Sage Therapeutics, Inc. (NASDAQ:SAGE), a biopharmaceutical company leading the way to create a world with better brain health, today announced the appointment of Jessica Federer to the company's Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230316005117/en/Jessica Federer (Photo: Business Wire) "We are thrilled to have Jessica join our Board of Directors. Jessica is a champion for patients and has a track record of innovation in data and digital transformation which will be a key future growth driver for the industry," said Barry Greene, Chief Executive Officer at Sage Therapeutics. "Jessica's innate curiosit

    3/16/23 6:30:00 AM ET
    $SAGE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SAGE
    Financials

    Live finance-specific insights

    View All

    Supernus Pharmaceuticals Completes Acquisition of Sage Therapeutics

    ROCKVILLE, Md., July 31, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) ("Supernus") today announced that it has successfully completed its previously announced acquisition of Sage Therapeutics, Inc. (NASDAQ:SAGE) ("Sage"). "Sage is an ideal fit in our corporate development strategy, adding a significant fourth growth product to our portfolio and further diversifying our sources of future revenue," said Jack Khattar, President and CEO of Supernus Pharmaceuticals. "With our proven track record of strong commercial execution along with the expected cost synergies, the acquisition is expected to be accretive in 2026." Compelling Strategic Rationale Strengthens psychi

    7/31/25 8:44:03 AM ET
    $SAGE
    $SUPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sage Therapeutics Announces Second Quarter 2025 Financial Results

    Achieved $23.2 million in ZURZUVAE® (zuranolone) collaboration revenue in the second quarter of 2025 (50% of the net revenues recorded by Biogen), representing a 68% increase from the first quarter Previously announced acquisition by Supernus Pharmaceuticals expected to close in third quarter of 2025 Cash, cash equivalents, and marketable securities of $366 million as of June 30, 2025 Sage Therapeutics, Inc. (NASDAQ:SAGE), today reported business highlights and financial results for the second quarter ended June 30, 2025. "Our second quarter results reflect revenue acceleration driven by increased investment, strong execution, and growing momentum behind ZURZUVAE, underscoring our c

    7/30/25 4:05:00 PM ET
    $SAGE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Supernus Pharmaceuticals to Acquire Sage Therapeutics, Strengthening its Neuropsychiatry Product Portfolio

    Proposed acquisition expected to accelerate mid- to long-term revenue and cash flow growth and further diversify revenue base.Strengthens Supernus' leading presence in neuropsychiatric conditions with an innovative commercial product, ZURZUVAE® (zuranolone), and a novel CNS discovery platform.Expected to be significantly accretive in 2026 with potential cost synergies of up to $200 million on an annual basis.Upfront cash payment of $8.50 per share, plus one non-tradable contingent value right (CVR) payable upon achieving certain specific milestones collectively worth up to $3.50 per share in cash, for an aggregate of up to approximately $795 million or $12.00 per share.Supernus to host confe

    6/16/25 7:00:06 AM ET
    $SAGE
    $SUPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SAGE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Sage Therapeutics Inc.

    SC 13G/A - Sage Therapeutics, Inc. (0001597553) (Subject)

    11/14/24 6:14:58 PM ET
    $SAGE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Sage Therapeutics Inc.

    SC 13G/A - Sage Therapeutics, Inc. (0001597553) (Subject)

    11/12/24 4:56:16 PM ET
    $SAGE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Sage Therapeutics Inc.

    SC 13G/A - Sage Therapeutics, Inc. (0001597553) (Subject)

    11/12/24 10:34:18 AM ET
    $SAGE
    Biotechnology: Pharmaceutical Preparations
    Health Care